Substance / Medication

Rasburicase

Overview

Active Ingredient
rasburicase
RxNorm CUI
283821

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

5 trials linked to this intervention

5
Total Trials
1
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Rasburicase-induced hemolytic anemia and methemoglobinemia: a systematic review of current reports.
Hammami M Bakri, Qasim Asma, Thakur Rahul et al. · Ann Hematol · 2024
PMID: 37468669Meta-Analysis
Rasburicase induced methemoglobinemia: A systematic review of descriptive studies.
Vidhyashree B H, Zuber Mohammed, Taj Shifa et al. · J Oncol Pharm Pract · 2022
PMID: 35119341Meta-Analysis
Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
Lopez-Olivo Maria A, Pratt Gregory, Palla Shana L et al. · Am J Kidney Dis · 2013
PMID: 23684124Meta-Analysis
Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
Feng X, Dong K, Pham D et al. · J Clin Pharm Ther · 2013
PMID: 23550846Meta-Analysis
[Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome].
Tatay V Sánchez, Castilla J D López, Ponce J M Carmona et al. · An Pediatr (Barc) · 2010
PMID: 20022572RCT
Effectiveness of rasburicase 4.5 mg in the treatment of tumor lysis syndrome-related hyperuricemia.
Schlueter Callahan, Stojova Emilija, Rozycki Elizabeth et al. · Am J Health Syst Pharm · 2025
PMID: 39673787Observational
Comparing Refrigeration to Immediate Room Temperature Testing for Uric Acid Monitoring in Rasburicase-Treated Patients.
Lin Leo, Filtz Michael, Wilson Jeffrey et al. · J Appl Lab Med · 2025
PMID: 39691998Observational
Rasburicase vs. allopurinol: mortality in hematological malignancies post anti-hyperuricemic therapy - real-world study.
Cairo Mitchell Stuart, Gallagher Jack Ray, Barnes Yvonne et al. · Support Care Cancer · 2025
PMID: 41225055ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Rasburicase (substance)
SNOMED CT
395858003
UMLS CUI
C0937932
RxNorm CUI
283821

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
5
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.